

Medical Necessity Guidelines

Neuromodulation for Overactive Bladder and Fecal Incontinence

Policy Number: 036

Contents

Overview.....	1
Medicare Advantage	1
Mass General Brigham ACO	2
One Care and Senior Care Options (SCO).....	2
Commercial and Qualified Health Plans.....	2
Definitions	6
Codes	7
Summary of Evidence	7
Effective Dates.....	9
References	9

Overview

The purpose of this document is to describe the guidelines Mass General Brigham Health Plan utilizes to determine medical appropriateness for neuromodulation, including percutaneous tibial nerve stimulation (PTNS), trial of sacral nerve neuromodulation, and permanent implantation of sacral nerve stimulation (SNS) as treatment for overactive bladder and fecal incontinence.

Medicare Advantage

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) for medical necessity determinations for its Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs), and documentation included in the Medicare manuals are the basis for medical necessity determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan's medical policies are used for medical necessity determinations. **At the time of Mass General Brigham Health Plan's most recent policy review, Medicare includes coverage guidelines for the following:**

- [LCD: Posterior Tibial Nerve Stimulation for Voiding Dysfunction \(L33396\)](#)
- [LCD: Sacral Nerve Stimulation for the Treatment of Urinary and Fecal Incontinence \(L39543\)](#)
- [NCD: Sacral Nerve Stimulation for Urinary Incontinence \(230.18\)](#)

When a provider for a Medicare Advantage member requests SNS that is not for the treatment of urinary incontinence, or requests PTNS, and that provider is located outside of the jurisdictions in which the LCDs above apply, Mass General Brigham Health Plan uses internal criteria (as described in this policy) to determine medical necessity. **Criteria for these members can be found in the Commercial and Qualified Health Plan section.**

Mass General Brigham ACO

Prior Authorization Required	Yes ☒ No ☐
No Authorization	A4290

Mass General Brigham Health Plan uses guidance from MassHealth for medical necessity determinations for its Mass General Brigham ACO members. When MassHealth does not have guidance available for specific DME, refer to the Medicare Variation for the relevant LCD. If no relevant LCD exists, refer to the Commercial and Qualified Health Plans section for medical necessity information. **At the time of Mass General Brigham Health Plan's most recent policy review, MassHealth did not have any medical necessity guidance for neuromodulation for overactive bladder or fecal incontinence. Refer to the Medicare Advantage section for medical necessity information.**

One Care and Senior Care Options (SCO)

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan uses guidance from CMS for medical necessity determinations for its One Care and SCO plan members. NCDs, LCDs, LCAs, and documentation included in the Medicare manuals are the basis for medical necessity determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan uses medical necessity guidelines from MassHealth. When there is no guidance from CMS or from MassHealth, Mass General Brigham Health Plan's medical policies are used for medical necessity determinations. **Refer to the Medicare Advantage section for medical necessity information.**

Commercial and Qualified Health Plans

Prior Authorization Required	Yes ☒ No ☐
------------------------------	---

Mass General Brigham Health Plan covers neuromodulation for the treatment of overactive bladder (OAB) and fecal incontinence when such treatment is recommended by the member's primary care physician or treating specialist, meets the medical necessity criteria indicated below, and is authorized prior to the procedure.

Percutaneous Tibial Nerve Stimulation

Overactive Bladder

Initial Treatment Assessment with PTNS

For the initial PTNS assessment, Mass General Brigham Health Plan covers a single 12-week trial of PTNS for the treatment of overactive bladder syndrome including urge incontinence and urgency frequency when all the following criteria are met:

1. The member is 18 years of age or older; and
2. The member has been diagnosed with OAB unrelated to a neurological condition with a thorough history, exam and appropriate testing when indicated; and
3. The provider has a well-documented and detailed symptom diary in order to gauge treatment outcomes; and
4. The member has contraindications to, or is refractory to conservative therapy including all of the following:
 - a. Behavioral training such as: habit training, prompted voiding, routine/scheduled toileting, fluid management, and pelvic floor exercise for 3 months; and



- b. Has failed, has a contraindication to or has been intolerant of at least 2 oral medications taken for at least 4 weeks (antimuscarinics, β -3-adrenoreceptor agonist, e.g., Mirabegron¹); and
- 5. Urge incontinence or urge frequency has resulted in significant disability to the member such that the frequency and/or severity of symptoms have resulted in limited activities of daily living; and
- 6. The member is willing and able to comply and has the cognitive capacity to participate with the treatment protocol during the testing phases. This is evidenced through the treating provider's medical notes.

Maintenance Treatment with PTNS

If the member has shown successful treatment of PTNS during the 12-week trial, a maximum of 26 treatments per initial 12-month period and maximum of 12-13 treatments per subsequent 12-month period is covered.

Successful treatment of PTNS is demonstrated when:

- 1. There is greater than 50% symptom relief of: number of daily episodes, severity of episodes and/or numbers of pads/diapers used, that is well documented in voiding diaries during the initial treatment phase.
- 2. The member is willing and able to comply and has the cognitive capacity to participate with the treatment protocol during the maintenance phases. This is evidenced through the treating provider's medical notes.

Exclusions

Mass General Brigham Health Plan does not provide coverage for PTNS in the following instances:

- 1. The member is under the age of 18.
- 2. Member who is incontinent due to mechanical obstruction, stress incontinence or neurologic disease origin.
- 3. A member has a condition such that PTNS is medically contraindicated. PTNS is contraindicated in patients who:
 - a. Have pacemakers;
 - b. Have implantable defibrillators;
 - c. Are pregnant or who plan to become pregnant during the duration of treatment.
- 4. Maintenance PTNS when initial treatment regimen failed. A failed treatment regimen is defined by less than 50% decrease in symptoms.
- 5. The member is unwilling or unable to comply with the treatment protocol and does not have the cognitive capacity to participate with the treatment protocol during the initial treatment and maintenance phases.
- 6. The member is unable to tolerate any conservative medical or behavioral therapy.

Sacral Nerve Stimulation (SNS)

Overactive Bladder

SNS always involves a two-step process. To be eligible for the first step members must meet criteria for PTNS eligibility and have exhausted non-surgical measures before moving on to SNS.

¹ Botox is covered by Mass General Brigham Health Plan for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults when pharmacy criteria are met, and it is authorized by Mass General Brigham Health Plan or affiliates.



The first step is done with a temporary electrode to determine if SNS reduces the symptoms of OAB. This step can be done by one of two procedures. Clinicians insert an electrode into the sacral nerve in an office-based procedure, percutaneous nerve evaluation (PNE), or under anesthesia during day surgery, Stage 1 Testing for SNS.

Initial Testing/Trial Period of SNS

Mass General Brigham Health Plan covers a 3–14-day trial of sacral nerve stimulation, through two different types of tests:

- PNE²; or
- Stage 1 Testing

A member must meet the following criteria to be eligible for SNS testing:

1. The member is 18 years of age or older; and
2. The member has been diagnosed with OAB or non-obstructive urinary retention unrelated to a neurological condition with a thorough history, exam, and appropriate testing if indicated; and
3. The provider has a well-documented and detailed symptom diary in order to gauge treatment outcomes; and
4. The member has contraindications to, intolerance or is refractory to conservative therapy including all of the following:
 - a. Behavioral training such as: habit training, prompted voiding, routine/scheduled toileting, fluid management and pelvic floor exercise for 6 months; and
 - b. At least 2 oral medications taken for at least 4 weeks (antimuscarinics, β -3-adrenoreceptor agonist, e.g., Mirabegron); and
5. Urge incontinence or urge frequency has resulted in significant disability to the member such that the frequency and/or severity of symptoms have resulted in limited activities of daily living; and
6. The member is an appropriate surgical candidate for the permanent implantation. A test/trial period of SNS is contraindicated in patients who:
 - a. Have pacemakers; and/or
 - b. Have implantable defibrillators; and/or
 - c. Are pregnant or who plan to become pregnant during the duration of treatment; and
7. The member is willing and able to comply with the treatment protocol and has the cognitive capacity to use the remote control to optimize device function during the testing and treatment phases.

Permanent Implantation of SNS

Mass General Brigham Health Plan covers one lifetime permanent implantation of a SNS device when all the following criteria are met:

1. The member has shown successful treatment during the SNS Test/Trial Period. Successful treatment is demonstrated by greater than or equal to 50% symptom relief of: number of daily episodes, severity of

²Mass General Brigham Health Plan may cover a stage 1 of a Two-Staged Tined Lead Procedure after a PNE that is inconclusive due to dislodgment. During the course of the staged implant, each stage of the procedure may be authorized only once, unless there are extraordinary clinical circumstances requiring replacement of the leads. The medical necessity for the latter must be documented in the medical record.



episodes and/or numbers of pads/diapers used, that is well documented in voiding diaries during the SNS Test/Trial Period; and

2. The member is willing and able to comply with the treatment protocol and has the cognitive capacity to use the remote control to optimize device function.

Note: Mass General Brigham Health Plan will authorize the replacement of the power supply of the permanent device when needed.

Note: Lifetime requirement does not include timed lead revision/battery replacement.

Exclusions

Mass General Brigham Health Plan does not provide coverage for Sacral Nerve Stimulation – Test/Trial or Permanent Implantation in the following instances:

1. A member has a condition such that SNS is medically contraindicated. SNS is contraindicated in members who:
 - a. Have pacemakers;
 - b. Have implantable defibrillators;
 - c. Are pregnant or who plan to become pregnant during the duration of treatment.
2. The member is under the age of 18.
3. Member who has urinary incontinence due to mechanical obstruction, stress incontinence, or neurologic disease origin.
4. The use of the implantable sacral nerve stimulation (including associated testing) when used with a member who is unwilling or unable to comply with the treatment protocol and/or does not have the cognitive capacity to use the remote control to optimize device function during the testing and treatment phases.

Fecal Incontinence

Initial Trial Phase of Implanted SNS

A screening trial of sacral nerve stimulation (SNS) with an external stimulator for either percutaneous nerve evaluation (PNE) or an implanted lead is considered medically necessary for the treatment of a diagnosis of fecal incontinence when ALL of the following criteria are met:

1. The member is/has been experiencing chronic fecal incontinence with greater than 2 incontinent episodes on average per week with duration greater than 6 months or more for at least 12 months after vaginal childbirth.
2. The member is an appropriate candidate for surgery.
3. There is documented failure, intolerance, or contraindication to conservative medical management (e.g., dietary management, pharmacotherapy, biofeedback, pelvic floor retraining)
4. There is no significant anorectal malformation or chronic inflammatory bowel disease involving the anus.
5. The condition is not related to chronic inflammatory bowel disease, chronic pelvic pain, or constipation;
6. The incontinence is not related to a neurologic condition such as peripheral neuropathy or complete spinal cord injury.



Permanent Implantation of SNS

Permanent SNS implantation for fecal incontinence is considered medically necessary when there has been a beneficial clinical response to a screening trial of SNS as evidenced by at least a 50% improvement in reported symptoms.

Mass General Brigham Health Plan considers sacral nerve stimulation for fecal incontinence experimental and investigational when these criteria are not met.

Definitions

Behavioral Training: A diverse group of interventions that improve urinary incontinence by changing a person's bladder habits and teaching new skills. These interventions can be used alone, in combination with each other, or as an adjunct to medication therapy.

Fecal Incontinence: The inability to control bowel movements leading to feces leaking from the rectum.

Overactive Bladder: Overactive Bladder (OAB) is the chronic condition associated with urinary urgency with or without urge incontinence and increased frequency.

Urinary Urgency: Uncontrollable urge to urinate.

Urge Incontinence: Involuntary leakage when there is a strong urge to void.

Increased Frequency: Voiding too often during the day.

Percutaneous Nerve Evaluation (PNE): Percutaneous Nerve Evaluation, also called percutaneous nerve stimulation, is a type of test that may be done prior to implantation of the permanent SNS device. During this outpatient procedure, a test needle is used to identify the appropriate sacral nerve. Once identified, a temporary electrode wire is placed in the patient (under local anesthesia) through the left or right S3 sacral foramen. The wire is secured with tape and connected to an external generator (stimulator) the patient wears for a trial period typically lasting three to seven days. Generally, at a minimum, a 50% improvement in one or more of the primary symptoms must be documented before a permanent stimulator can be implanted.

Percutaneous Tibial Nerve Stimulation (PTNS): Percutaneous Tibial Nerve Stimulation, also known as posterior tibial nerve stimulation, as well as peripheral tibial nerve stimulation, is a type of neuromodulation, which is less invasive than the alternative SNS. A slim needle electrode is inserted near the ankle. The needle electrode is then connected to the battery-powered stimulator. During treatment, mild impulses from the stimulator travel through the needle electrode along the posterior tibial nerve and to the sacral plexus, the nerves in the pelvic that controls bladder function. The exact mechanism of action is not precisely understood.

Percutaneous Tibial Nerve Stimulation Initial Treatment Regimen: A treatment regimen for PTNS is defined as 30-minute sessions given weekly for 12 weeks.

Sacral Nerve Stimulation (SNS): Sacral Nerve Stimulation (SNS), also known as sacral neuromodulation, is defined as the implantation of a permanent device (a pulse generator) that modulates the neural pathways controlling bladder function. A surgeon implants the small device under the skin, usually above the buttock. Attached to the device is a thin, electrode-tipped wire that carries controlled electrical impulses to the sacral nerves. Two external components of the system help control the electrical stimulation; a control magnet that the patient uses to turn the device on and off, and a device that allows programming and adjustments.

Two-Stage Tined Lead Procedure for Sacral Nerve Stimulation: A type of test that may be done prior to implantation of the permanent SNS device (this test is used in the initial testing/trial phase). In the first stage, a tined lead is implanted. The tined lead has an insulated electrical conductor with one end electrically connected to a pulse generator. The testing phase can last as long as a few weeks, and if patients show a 50% or greater



reduction in symptom frequency, the treating physician can proceed to stage two, which is the permanent implantation of the SNS device.

Urinary Retention: The inability to completely empty the bladder during urination.

Codes

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage or reimbursement.

Authorized Code	Code Description
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming
64581	Incision for implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
A4290	Sacral nerve stimulation test lead, each

Summary of Evidence

Percutaneous Tibial Nerve Stimulation (PTNS)

PTNS is a minimally invasive neuromodulation therapy used to treat overactive bladder (OAB) in patients who do not achieve adequate symptom control with behavioral therapy or pharmacologic management. PTNS delivers electrical stimulation to the posterior tibial nerve, which shares sacral nerve roots (S2–S4) involved in bladder control, thereby modulating afferent signaling and improving bladder storage function. Current clinical guidelines from the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) recommend PTNS for idiopathic OAB for patients who have had an inadequate response to, or experienced intolerable side effects from, pharmacotherapy or behavioral therapy (Cameron et al., 2024).

Evidence from randomized controlled trials supports the efficacy of PTNS in reducing OAB symptoms. In the SUMiT trial, a multicenter randomized sham-controlled study, 54.5% of patients receiving PTNS reported moderate or marked improvement in symptoms, compared with 20.9% in the sham-treatment group (Peters et al., 2010). Participants treated with PTNS experienced significant reductions in urinary frequency, urgency episodes, and urgency urinary incontinence, demonstrating that PTNS provides benefit beyond placebo effects.

Long-term follow-up studies indicate that symptom improvement with PTNS can be sustained with maintenance therapy. The STEP study showed that among patients who responded to initial treatment, 77% maintained moderate to marked improvement at 3 years, with an average of approximately one maintenance session per month (Peters et al., 2013). These findings suggest that PTNS offers durable symptom control for OAB when ongoing therapy is maintained. Systematic reviews further support the role of PTNS in OAB management. A comprehensive review by Gaziev et al. (2013) reported overall response rates of more than 50%, depending on patient selection and outcome definitions.

PTNS is associated with a favorable safety profile. Adverse events are uncommon and generally mild, consisting primarily of transient discomfort, bruising, or skin irritation at the needle insertion site. No major complications are reported in the literature (Gaziev et al., 2013). Compared with other third-line therapies such as sacral neuromodulation or intradetrusor botulinum toxin injections, PTNS avoids surgical implantation and device-



related risks, although it requires repeated clinic visits. Overall, the literature supports PTNS as a safe, effective, and durable treatment option for patients with refractory OAB.

Sacral Nerve Stimulation (SNS)

SNS is an established therapy for OAB in patients who fail to achieve adequate symptom control with behavioral and pharmacologic treatments. SNS involves electrical stimulation of the sacral nerve roots, typically S3, which play a critical role in bladder storage and voiding reflexes. Current clinical guidelines from the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), as well as European Association of Urology (EAU) guidelines, recommend SNS as an effective treatment option for refractory OAB in patients who are open to surgical treatment (Cameron et al., 2024; Gacci et al., 2022).

Randomized controlled trials and prospective studies demonstrate that SNS significantly improves OAB symptoms. In a prospective, randomized multicenter trial comparing SNS with standard medical therapy, patients treated with SNS experienced significantly greater reductions in urgency, frequency, and urgency urinary incontinence at 6 months (Siegel et al., 2015). Across clinical trials, 70–80% of patients undergoing stimulation achieve at least a 50% improvement in symptoms, with complete recovery occurring in 39–47% of patients after six months (Oelke et al., 2019). These improvements include reductions of 2–3 urgency incontinence episodes per day and meaningful improvements in quality-of-life scores. Long-term studies support the durability of SNS for OAB. Five-year follow-up data from a large multicenter study showed that approximately 67% of patients maintained therapeutic success at 5 years, with sustained improvements in urinary urgency and incontinence (Siegel et al., 2018).

Safety and adverse events associated with SNS are well documented. Device-related complications include pain at the implant site, lead migration, infection, and need for surgical revision. Reported adverse event rates are approximately 40% over long-term follow-up, although serious complications are uncommon (Oelke et al., 2019). Advances in device technology, including rechargeable and MRI-compatible systems, have improved patient convenience and long-term usability (Food and Drug Administration [FDA], n.d.; Hayes, 2020).

Comparative effectiveness studies indicate that SNS provides symptom control comparable to or better than other therapies. In women with refractory urgency urinary incontinence, SNS demonstrated similar efficacy to intradetrusor onabotulinumtoxinA, though each therapy has distinct risk profiles (Amundsen et al., 2016). Economic and technology assessments conclude that SNS is an effective long-term treatment option despite higher upfront costs, particularly for patients with severe or persistent symptoms (Hayes, 2010).

Overall, sacral nerve stimulation is a well-supported, durable, and effective therapy for refractory overactive bladder, offering sustained symptom relief for a majority of appropriately selected patients. While it is more invasive than percutaneous tibial nerve stimulation, SNS remains a cornerstone therapy for patients requiring long-term neuromodulation and is strongly supported by clinical guidelines and long-term outcome data.

SNS is also an established therapy for patients with fecal incontinence (FI) who do not respond adequately to conservative treatments such as dietary modification, medications, and pelvic floor therapy. Clinical guidelines and consensus statements recognize SNS as an effective treatment for moderate to severe FI, supported by evidence from randomized trials, prospective cohort studies, and long-term follow-up data (Maeda et al., 2011; Tjandra et al., 2008).

Randomized controlled trials demonstrate that SNS is superior to optimal medical therapy for FI. In a pivotal randomized study, Tjandra et al. (2008) reported that 90% of patients treated with SNS achieved at least a 50% reduction in weekly fecal incontinence episodes, compared with no significant improvement in the medically managed group. Complete continence was achieved in 47% of SNS patients. These findings established SNS as an effective therapy for severe FI refractory to standard care.



Prospective multicenter studies further support the efficacy of SNS. In a large multicenter trial of 120 patients, Wexner et al. (2010) found that approximately 83% of patients maintained a $\geq 50\%$ reduction in FI episodes at 12 months, along with significant improvements in quality-of-life measures. Improvements were observed across multiple FI etiologies, including idiopathic, obstetric-related, and postsurgical incontinence. Long-term durability of SNS has been demonstrated in extended follow-up studies. A French multicenter cohort with up to 10 years of follow-up showed long-term efficacy was maintained in approximately half of patients treated with SNS (Desprez et al., 2022).

Adverse events associated with SNS are generally related to the implanted device. Common complications include pain at the implant site, lead migration, infection, and need for device revision, but serious complications remain uncommon (Maeda et al., 2011). Despite these risks, overall patient satisfaction remains high due to substantial symptom improvement and quality-of-life gains.

Overall, the evidence supports sacral nerve stimulation as a safe, effective, and durable treatment for fecal incontinence in appropriately selected patients. Randomized trials, multicenter studies, and long-term observational data consistently demonstrate significant reductions in incontinence episodes and sustained clinical benefit, making SNS a cornerstone therapy for refractory fecal incontinence.

Effective Dates

December 1, 2026: Ad hoc review. Updated ACO section.

February 2026: Annual review. Reformatted policy. Summary of evidence and references updated.

January 2026: Ad hoc review. Updated prior authorization table and added variation for One Care and SCO members.

September 2025: Ad hoc review. Summary of evidence added. Code disclaimer and references updated.

March 2025: Annual review. LCD added. Prior authorization table at top of policy fixed.

February 2025: Ad hoc review. Codes updated. Added reference to custom InterQual® subset.

December 2024: Ad hoc review. Added MassHealth variation language.

March 2024: Annual review.

March 2023: Annual review. Medicare Advantage added to table. Added Medicare variation language. References updated.

April 2022: Annual review. Under Percutaneous Tibial Nerve Stimulation, added exclusion “The member is unable to tolerate any conservative medical or behavioral therapy”. Under Initial Testing/Trial Period of SNS, removed criteria restricting trial to one lifetime. Added Fecal Incontinence criteria. Under Definitions, Added Fecal Incontinence. References updated.

March 2021: Annual review. Minor edit to footnote on page 1. References updated.

April 2020: Annual review. Under Initial Treatment Assessment with PTNS, changed behavioral training requirement period from 6 months to 3 months. References updated.

April 2019: Annual review. Under Initial Treatment Assessment with PTNS, revised criteria under #2b from two antimuscarinics to two oral medications. Under Permanent Implantation of SNS section, under item #1 changed criteria from greater than 50% symptom relief to greater than or equal to.

April 2018: Annual review.

February 2017: Effective date

References

Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. *JAMA*. 2016 Oct 4;316(13):1366-1374. doi: 10.1001/jama.2016.14617. PMID: 27701661; PMCID: PMC5399419.



Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. *J Urol*. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. <https://www.auajournals.org/doi/10.1097/JU.0000000000003985>

Capitanucci ML, Camanni D, Demelas F, et al. Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children. *J Urol*. 2009;182:2056-2061.

Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. *J Urol*. 2012;187:178-74.

Desprez C, Damon H, Meurette G, et al. Ten-year Evaluation of a Large Retrospective Cohort Treated by Sacral Nerve Modulation for Fecal Incontinence: Results of a French Multicenter Study. *Ann Surg*. Apr 01 2022; 275(4): 735-742. PMID 32740249

Dorsthurst MJ, Digesu GA, Tailor V, et al. 3-year followup of a new implantable tibial nerve stimulator for the treatment of overactive bladder syndrome. *J Urol*. 2020;204:545-50.

Ferreira R, Alwashmi E, Otis-Chapados S, et al. Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence. *Can J Urol*. 2024 Aug;31(4):11943-11949. PMID: 39217518.

Food and Drug Administration (FDA). Summary of Safety and Effectiveness: Medtronic Interstim System for Urinary Control. http://www.accessdata.fda.gov/cdrh_docs/pdf/P970004S004b.pdf

Gacci M, Sakalis VI, Karavitakis M, et al. European Association of Urology Guidelines on Male Urinary Incontinence. *Eur Urol*. 2022 Oct;82(4):387-398. doi: 10.1016/j.eururo.2022.05.012. Epub 2022 Jun 11. PMID: 35697561.

Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. *BMC Urol*. 2013 Nov 25;13:61. doi: 10.1186/1471-2490-13-61. PMID: 24274173; PMCID: PMC4222591.

Hayes Inc. Hayes Medical Technology, Health directory, Implantable sacral nerve stimulation for urinary voiding dysfunction. July 12, 2010.

Hayes Inc. Hayes Medical Technology, Percutaneous tibial nerve stimulation for the treatment of lower urinary tract dysfunction. November 19, 2015.

Hayes Inc. Hayes Medical Technology Directory, Comparative Effectiveness Review: Percutaneous Tibial Nerve Stimulation for the Treatment of Symptomatic Non-Neurogenic Overactive Bladder Syndrome. October 31, 2018.

Hayes. Clinical Research Response. Axonics (Axonics Neuromodulation Technologies Inc.) Versus InterStim (Medtronic) Sacral Neuromodulation Systems for Urinary or Fecal Incontinence. October 16, 2020.

High RA, Winkelman W, Panza J, et al. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference? *Int Urogynecol J*. 2021 Jan;32(1):149-157. doi: 10.1007/s00192-020-04392-4. Epub 2020 Jun 25. PMID: 32588075.

Iyer S, Laus K, Rugino A, et al. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. *Int Urogynecol J*. 2019 Aug;30(8):1253-1259. doi: 10.1007/s00192-018-3822-0. Epub 2018 Nov 22. PMID: 30467763.



Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. *Eur Urol*. 2010 Dec;58(6):865-74. doi: 10.1016/j.eururo.2010.09.024. Epub 2010 Oct 1. PMID: 20934242.

Marinkovic SP, Ford JC. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages [1-9V] during Stage 1 sacral neuromodulation. *BJU Int* 2018; 122: 472–479

Maeda Y, Matzel K, Lundby L, et al. Postoperative issues of sacral nerve stimulation for fecal incontinence and constipation: a systematic literature review and treatment guideline. *Dis Colon Rectum*. Nov 2011; 54(11): 1443-60. PMID 21979192

Oelke M, Addali M, Reisenauer C. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder. *Arch Gynecol Obstet*. 2019 May;299(5):1243-1252. doi: 10.1007/s00404-019-05127-7. Epub 2019 Apr 2. PMID: 30941558.

Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUMiT trial. *J Urol*. 2010 Apr;183(4):1438-43. doi: 10.1016/j.juro.2009.12.036. Epub 2010 Feb 20. PMID: 20171677.

Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. *J Urol*. 2013;189:2194-2201.

Picciariello A, Rinaldi M, Dibra R, et al. Ageing with sacral nerve modulation for fecal incontinence: how many patients get benefit after more than 10 years? *Updates Surg*. Feb 2022; 74(1): 185-191. PMID 34982410

Schneider MP, Gross T, Bachmann LM, et al. Tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. *Eur Assoc Urol*. 2015;68:859-867.

Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. *Neurourol Urodyn* 2015; 34: 224.

Siegel S, Noblett K, Mangel J, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. *J Urol*. 2018 Jan;199(1):229-236. doi: 10.1016/j.juro.2017.07.010. Epub 2017 Jul 11. PMID: 28709886.

Tjandra JJ, Chan MK, Yeh CH, et al. Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study. *Dis Colon Rectum*. May 2008; 51(5): 494-502. PMID 18278532

Wexner SD, Collier JA, Devroede G, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. *Ann Surg*. Mar 2010; 251(3): 441-9. PMID 20160636

